ASX Biotech/Company Directory

/

descriptionAnnouncements scienceTrials warningRisk Matrix bookmarkWatchlist feedbackFeedback settingsSettings

CSLCSL Limited

data caveat$62.7BCF+

Companies/CSL

CSLActiveTier 1

CSL Limited

Biotech · Blood products / Vaccines

Global leader in plasma-derived therapies, vaccines (Seqirus), and recombinant products

Website ↗ASX ↗

Data HealthTrials25 of 28 active · stale enrollment

Cash data from Dec 2025 4CFigures from ASX filings · not financial advice

[ VITALS ]

Cash on Hand

$1.8B

Dec 2025 4C

Runway

CF+Cash Flow Positive

Based on Dec 2025 4C

Market Cap

$62.7B

Burn Rate

—

Dec 2025 4C

Shares Outstanding

485M

Pipeline Assets

CSL

Latest Insight(1)

21 Apr 2026

buybackUpdate - Notification of buy-back - CSL

$9.0M·On-Market·66,092 shares

picture_as_pdfView full announcement

3M Price

CSL.ASX

$129.190-26.7% 3M

Low $129.190High $179.970

Pipeline Assets (3)

GaradacimabHereditary angioedema prevention

Phase 3

CSL112 (apoA-I)Acute coronary syndrome

Phase 3

HemgenixHaemophilia B gene therapy

Approved

Discovery

Preclinical

Ph 1

Ph 1/2

Ph 2

Ph 2/3

Ph 3

Capital Raises & Buybacks

15 buybacks

Current shares outstanding: 485M

Buyback

Director Options & Rights

Director

Outstanding

Ex. Price

Expiry

No option data entered yet

Short Interest

ASIC ↗as of 2026-03-27 · 4-day lag

Short position

0.74%

arrow_drop_up+0.05% over 30 reports

Shares short

3.6M

Aggregated short position data published by ASIC under the Corporations Act. T+4 reporting lag applies. Short interest ≥5% is noteworthy; ≥10% is elevated. Source: ASIC Short Selling Data

Competitive Landscape

86 competitor trialsPhase 2+ · Non-ASX

Hereditary Angioedema Prevention7 active trials

7 Ph3

Acute Coronary Syndrome70 active trials

40 Ph414 Ph34 Ph2/312 Ph2

Haemophilia B Gene Therapy9 active trials

3 Ph31 Ph2/31 Ph24 Ph1/PHASE2

Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.

expand_more

Clinical Publications

Peer-reviewed papers & conference abstracts via PubMed

15 papers

The ApoB/ApoA-I ratio supersedes conventional lipids in predicting coronary artery disease and clinical phenotypes requiring revascularization.

Clin Exp Hypertens2026-12· apoA-I

Tumor microenvironment-responsive conformational activation of apoA-I mimetic peptides for targeted cancer therapy.

Drug Deliv2026-12· apoA-I

Transferability and Between Laboratory Imprecision of an LC-MS/MS-Based Reference Measurement Procedure for Apolipoproteins.

Clin Chem2026-04· apoA-I

Factor XII in Thrombosis and Thromboinflammation: From Molecular Biology to Clinical Translation.

Int J Mol Sci2026-04· GaradacimabReview

Catalysts (175)· 23 upcoming · 152 past

CSL112 Phase 3 AEGIS-II readout

Upcoming

Expectedarrow_upwardHigh30 June 2026

Seqirus flu vaccine season

Upcoming

ConfirmedremoveMed30 June 2026

Garadacimab FDA filing decision

Upcoming

Expectedarrow_upwardHigh30 Sept 2026

PHASE2 data readout — Zemaira Eosinophilic Esophagitis Pilot Studyopen_in_new

Delivery Consistency Index

Historical delivery and spending consistency — data is limited for recently added companies.

Delivery Consistency Index

Delivery

–Insufficient data

0/3 data points needed

Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts

Capital discipline

–Insufficient data

1/2 data points needed

Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus

Filing discipline not scored — this company reports under US regime (Form 10-K / 10-Q). ASX Listing Rule 4.7C deadlines don't apply.

Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.

These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.

⚠ TIMELINE CHANGESCT.GOV · AUTO-DETECTED

These changes were automatically detected by comparing ClinicalTrials.gov records over time. A slipped date means the trial's expected completion moved later; pulled forward means it moved earlier.

↗ SLIPPED

NCT06699849 ↗2027-08-07 → 2027-10-22(3mo delay)

2026-04-20

★ RESULTS

NCT01199705 ↗Results posted to ClinicalTrials.gov

2026-04-13

★ RESULTS

NCT01496274 ↗Results posted to ClinicalTrials.gov

2026-04-13

★ RESULTS

NCT01545076 ↗Results posted to ClinicalTrials.gov

2026-04-13

★ RESULTS

Clinical Trials(65)

28 activeClinicalTrials.gov ↗

RecruitingOBSERVATIONALEnrollment stale · 675d

Precision Medicine in Cardiovascular Surgery Associated Acute Kidney Injury

Acute Kidney Injury · Surgery-Complications · Frailty

18 Years+

Primary endpoint Change from baseline of serum Fetuin-A values

NCT06471621 ↗CT.gov

Start

2024-06

Primary end

2026-01

RecruitingOBSERVATIONALEnrollment stale · 1042d

HEMGENIXFactor IX (FIX)

An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B

Hemophilia B

18 Years+

Primary endpoint Bleeding Rate (all bleeds) - HEMGENIX Cohort

NCT06008938 ↗CT.gov

Start

2023-06

Primary end

2043-08

RecruitingOBSERVATIONALEnrollment stale · 5531d

Australian and New Zealand Massive Transfusion Registry

Massive Transfusion · Trauma · Cardiothoracic Surgery +4 more

18 Years+

Primary endpoint Mortality

NCT02863250 ↗CT.gov

Start

2011-03

Primary end

2028-12

Announcements(15)

All announcements →

article

buybackauto_awesome

Update - Notification of buy-back - CSL

21 Apr 2026

15KB

expand_more

article

buybackauto_awesome

Update - Notification of buy-back - CSL

20 Apr 2026

15KB

expand_more

article

Other

Notification of cessation of securities - CSL

19 Apr 2026

12KB

article

buybackauto_awesome

Update - Notification of buy-back - CSL

7 Apr 2026

15KB

expand_more

article

Other

U.S. Section 232 Tariffs on Pharmaceuticals

6 Apr 2026

125KB

Event	Type	Confidence	Impact	Date	Status
CSL112 Phase 3 AEGIS-II readout Pivotal trial of apolipoprotein A-I in acute coronary syndrome, data expected 2026	data readout	Expected	arrow_upwardHigh	30 June 2026	Upcoming
Seqirus flu vaccine season Southern hemisphere influenza vaccine revenue for 2026 season	commercial milestone	Confirmed	removeMed	30 June 2026	Upcoming
Garadacimab FDA filing decision Phase 3 data for hereditary angioedema prevention submitted to FDA	regulatory decision	Expected	arrow_upwardHigh	30 Sept 2026	Upcoming
PHASE2 data readout — Zemaira Eosinophilic Esophagitis Pilot Studyopen_in_new Primary completion expected for NCT05485155. Indication: {"Eosinophilic Esophagitis"}	data readout	Speculative	removeMed	1 Oct 2026	Upcoming
PHASE3 data readout — Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adulopen_in_new Primary completion expected for NCT07094087. Indication: {"Complex Cardiovascular Surgery With Cardiopulmonary Bypass"}	data readout	Speculative	removeMed	18 Nov 2026	Upcoming
PHASE3 data readout — Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) iopen_in_new Primary completion expected for NCT06399289. Indication: {"Hemophilia B"}	data readout	Speculative	removeMed	1 Dec 2026	Upcoming
PHASE2 data readout — Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With open_in_new Primary completion expected for NCT06699849. Indication: {"Sickle Cell Disease Vaso-occlusive Crisis"}	data readout	Speculative	removeMed	7 Aug 2027	Upcoming
PHASE3 data readout — Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Popen_in_new Primary completion expected for NCT06617897. Indication: {"Acquired Fibrinogen Deficiency"}	data readout	Speculative	removeMed	1 Sept 2027	Upcoming
Trial data readout — Hizentra® in Inflammatory Neuropathies - pHeNIx Studyopen_in_new Primary completion expected for NCT04672733. Indication: {"Chronic Inflammatory Demyelinating Polyneuropathy"}	data readout	Speculative	removeMed	1 Dec 2027	Upcoming
Trial data readout — Observatory of Patients With Haemophilia B Treated by IdElvion®open_in_new Primary completion expected for NCT05086575. Indication: {"Haemophilia B"}	data readout	Speculative	removeMed	1 Dec 2027	Upcoming
PHASE2 data readout — Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults Witopen_in_new Primary completion expected for NCT07048262. Indication: {"Non-cystic Fibrosis Bronchiectasis"}	data readout	Speculative	removeMed	28 Feb 2028	Upcoming
PHASE2 data readout — Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Reopen_in_new Primary completion expected for NCT07332091. Indication: {"Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis"}	data readout	Speculative	removeMed	6 Mar 2028	Upcoming
PHASE2 data readout — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)open_in_new Primary completion expected for NCT07224360. Indication: {"Sickle Cell Disease"}	data readout	Speculative	removeMed	29 June 2028	Upcoming
Trial data readout — A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Popen_in_new Primary completion expected for NCT07001280. Indication: {"Hereditary Angioedemas"}	data readout	Speculative	removeMed	31 Aug 2028	Upcoming
PHASE3 data readout — Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adultsopen_in_new Primary completion expected for NCT06003387. Indication: {"Hemophilia B"}	data readout	Speculative	removeMed	4 Oct 2028	Upcoming
Trial data readout — Australian and New Zealand Massive Transfusion Registryopen_in_new Primary completion expected for NCT02863250. Indication: {"Massive Transfusion",Trauma,"Cardiothoracic Surgery","Gastrointestinal Bleeding","Vascular Surgery","Obstetric Bleeding","Liver Transplant"}	data readout	Speculative	removeMed	31 Dec 2028	Upcoming
PHASE2/PHASE3 data readout — Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult open_in_new Primary completion expected for NCT05485961. Indication: {"Atherosclerotic Cardiovascular Disease","End Stage Kidney Disease","Atherosclerotic Cardiovascular Disease in Patients With ESKD"}	data readout	Speculative	removeMed	27 Sept 2029	Upcoming
PHASE4 data readout — Two Dose Levels of Privigen in Pediatric CIDPopen_in_new Primary completion expected for NCT03684018. Indication: {"Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)"}	data readout	Speculative	removeMed	20 Dec 2029	Upcoming
PHASE4 data readout — Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) open_in_new Primary completion expected for NCT07326592. Indication: {"Alpha1 Antitrypsin Deficiency","Alpha1-Proteinase Inhibitor Deficiency",Emphysema}	data readout	Speculative	removeMed	15 Sept 2033	Upcoming
PHASE3 data readout — Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ open_in_new Primary completion expected for NCT07080905. Indication: {"Hemophilia B"}	data readout	Speculative	removeMed	24 Oct 2033	Upcoming
Trial data readout — Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated Wiopen_in_new Primary completion expected for NCT05962398. Indication: {"Hemophilia B"}	data readout	Speculative	removeMed	23 Mar 2035	Upcoming
Trial data readout — ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disordersopen_in_new Primary completion expected for NCT04398628. Indication: {"Hematologic Disorder","Bleeding Disorder","Connective Tissue Disorder",Hemophilia,Thrombosis,"Von Willebrand Diseases",Thrombophilia,"Rare Bleeding Disorder","Platelet Disorder","Factor IX Deficiency","Factor VIII Deficiency",Thalassemia,"Sickle Cell Disease"}	data readout	Speculative	removeMed	1 June 2035	Upcoming
Trial data readout — An Observational Cohort Study to Characterize the Effectiveness and Safety of HEopen_in_new Primary completion expected for NCT06008938. Indication: {"Hemophilia B"}	data readout	Speculative	removeMed	1 Aug 2043	Upcoming

expand_more152 past catalysts

Results posted — A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs open_in_new Results available at https://clinicaltrials.gov/study/NCT01700036	data readout	Confirmed	arrow_upwardHigh	8 Apr 2026	Completed
Results posted — RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgeryopen_in_new Results available at https://clinicaltrials.gov/study/NCT01283321	data readout	Confirmed	arrow_upwardHigh	8 Apr 2026	Completed

CSL Limited

Latest Insight(1)

3M Price

Pipeline Assets (3)

Capital Raises & Buybacks

Director Options & Rights

Short Interest

Competitive Landscape

Clinical Publications

Catalysts (175)· 23 upcoming · 152 past

Delivery Consistency Index

Clinical Trials(65)

Announcements(15)

Quarterly Cash Flow